Based on hydrocodone component: Hypersensitivity to hydrocodone or any component of the formulation
Based on aspirin component: Hypersensitivity to salicylates, other NSAIDs, or any component of the formulation; asthma; rhinitis; nasal polyps; inherited or acquired bleeding disorders (including factor VII and factor IX deficiency); pregnancy (in 3rd trimester especially); do not use in children (<16 years) for viral infections (chickenpox or flu symptoms), with or without fever, due to a potential association with Reye's syndrome
Based on hydrocodone component: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (morphine, codeine, hydromorphone, levorphanol, oxycodone, oxymorphone); should be used with caution in elderly or debilitated patients, and those with severe impairment of hepatic or renal function, prostatic hyperplasia, or urethral stricture. Also use caution in patients with head injury, increased intracranial pressure, acute abdomen, or impaired thyroid function. Hydrocodone suppresses the cough reflex; caution should be exercised when this agent is used postoperatively and in patients with pulmonary diseases (including asthma, emphysema, COPD)
Based on aspirin component: Use with caution in patients with platelet and bleeding disorders, renal dysfunction, dehydration, erosive gastritis, or peptic ulcer disease. Heavy ethanol use (>3 drinks/day) can increase bleeding risks. Avoid use in severe renal failure or in severe hepatic failure. Discontinue use if tinnitus or impaired hearing occurs. Caution in mild-moderate renal failure (only at high dosages). Patients with sensitivity to tartrazine dyes, nasal polyps and asthma may have an increased risk of salicylate sensitivity. Surgical patients should avoid ASA if possible, for 1-2 weeks prior to surgery, to reduce the risk of excessive bleeding.
>10%:
Cardiovascular: Hypotension
Central nervous system: Lightheadedness, dizziness, sedation, drowsiness, fatigue
Gastrointestinal: Nausea, heartburn, stomach pain, dyspepsia, epigastric discomfort
Neuromuscular & skeletal: Weakness
1% to 10%:
Cardiovascular: Bradycardia
Central nervous system: Confusion
Dermatologic: Rash
Gastrointestinal: Vomiting, gastrointestinal ulceration
Genitourinary: Decreased urination
Hematologic: Hemolytic anemia
Respiratory: Dyspnea
Miscellaneous: Anaphylactic shock
<1%: Hypertension, hallucinations, insomnia, nervousness, jitters, xerostomia, anorexia, biliary tract spasm, urinary tract spasm, occult bleeding, prolongated bleeding time, leukopenia, thrombocytopenia, iron-deficiency anemia, hepatotoxicity, diplopia, miosis, impaired renal function, bronchospasm, histamine release, physical and psychological dependence with prolonged use
Based on hydrocodone component: Substrate of CYP2D6 (major)
CNS depressants, MAO inhibitors, general anesthetics, and tricyclic antidepressants: May potentiate the effects of opiate agonists; dextroamphetamine may enhance the analgesic effect of opiate agonists.
CYP2D6 inhibitors: May decrease the effects of hydrocodone. Example inhibitors include chlorpromazine, delavirdine, fluoxetine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, and ropinirole.
Based on aspirin component: Substrate of CYP2C8/9 (minor)
ACE inhibitors: The effects of ACE inhibitors may be blunted by aspirin administration, particularly at higher dosages.
Buspirone increases aspirin's free % in vitro .
Carbonic anhydrase inhibitors and corticosteroids have been associated with alteration in salicylate serum concentrations.
Heparin and low molecular weight heparins: Concurrent use may increase the risk of bleeding
Methotrexate serum levels may be increased; consider discontinuing aspirin 2-3 days before high-dose methotrexate treatment or avoid concurrent use.
NSAIDs may increase the risk of gastrointestinal adverse effects and bleeding. Serum concentrations of some NSAIDs may be decreased by aspirin.
Platelet inhibitors (IIb/IIIa antagonists): Risk of bleeding may be increased.
Probenecid effects may be antagonized by aspirin.
Sulfonylureas: The effects of older sulfonylurea agents (tolazamide, tolbutamide) may be potentiated due to displacement from plasma proteins. This effect does not appear to be clinically significant for newer sulfonylurea agents (glyburide, glipizide, glimepiride).
Valproic acid may be displaced from its binding sites which can result in toxicity.
Verapamil may potentiate the prolongation of bleeding time associated with aspirin.
Warfarin and oral anticoagulants may increase the risk of bleeding.
Based on hydrocodone component: Ethanol: Avoid or limit ethanol (may increase CNS depression). Watch for sedation.
Based on aspirin component:
Ethanol: Avoid ethanol (may enhance gastric mucosal damage).
Food: Food may decrease the rate but not the extent of oral absorption. Take with food or or large volume of water or milk to minimize GI upset.
Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, ginseng (all have additional antiplatelet activity).
Based on hydrocodone component: Binds to opiate receptors in the CNS, altering the perception of and response to pain; suppresses cough in medullary center; produces generalized CNS depression
Based on aspirin component: Inhibits prostaglandin synthesis, acts on the hypothalamus heat-regulating center to reduce fever, blocks prostaglandin synthetase action which prevents formation of the platelet-aggregating substance thromboxane A2
Aspirin: See Aspirin monograph.
Hydrocodone:
Onset of action: Narcotic analgesic: 10-20 minutes
Duration: 4-8 hours
Distribution: Crosses placenta
Metabolism: Hepatic; O-demethylation; N-demethylation and 6-ketosteroid reduction
Half-life elimination: 3.3-4.4 hours
Excretion: Urine
Dionne RA, "New Approaches to Preventing and Treating Postoperative Pain," J Am Dent Assoc , 1992, 123(6):26-34.
Gobetti JP, "Controlling Dental Pain," J Am Dent Assoc , 1992, 123(6):47-52.
Mokhlesi B, Leikin JB, Murray P, et al, "Adult Toxicology in Critical Care: Part II: Specific Poisonings," Chest , 2003, 123(3):897-922.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |